## SUPPLEMENTARY INFORMATION

Supplementary Table 1. Full search phrases used for MEDLINE and EMBASE on 4 August 2020

| Ovid MEDLINE |  |
| :--- | :--- |
| Cervical spine concept |  |
| 1 | exp Cervical Vertebrae/ or exp Cervical Cord/ or cervical.tw |
| DCM concept |  |
| 2 | Exp Spinal Cord Diseases/ or Exp Spinal Diseases/ |
| 3 | degenerat*.tw |
| 4 | 2 and 3 |
| 5 | Myelopath*.tw |
| 6 | Myeloradiculopath*.tw |
| 7 | Radiculopath*.tw |
| 8 | Exp Spinal Cord Compression/ |
| 9 | Exp "Ossification of the Posterior Longitudinal Ligament"/ |
| 10 | Ossification of the Posterior Longitudinal Ligament.tw |
| 11 | OPLL.tw |
| 12 | Exp Spinal Stenosis/ |
| 13 | Cervical stenosis.tw |
| 14 | Exp Spondylosis/ |
| 15 | Spondylosis.tw |
| 16 | Spondylotic.tw |
| 17 | Degenerative cervical myelopathy.tw |
| 18 | DCM.tw |
| 19 | Cervical spondylotic myelopathy.tw |
| 20 | CSM.tw |
| 21 | 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 |
| 22 | 1 and 21 |
| Tools for function concept (neurological/gait/mobility centric) concept |  |
| 23 | Japanese Orthopaedic Association score.tw |
| 24 | JOA.tw |
| 25 | modified JOA.tw |
| 26 | mJOA.tw |
| 27 | Graded Redefined Assessment of Sensation Strength and Prehension.tw |


| 31 | Myelopathy Disability Index.tw |
| :---: | :---: |
| 32 | MDI.tw |
| 33 | Nurick score.tw |
| 34 | Neck functional disability scale.tw |
| 35 | NFDS.tw |
| 36 | Neck Disability Index.tw |
| 37 | NDI.tw |
| 38 | Cooper myelopathy scale.tw |
| 39 | CMS.tw |
| 40 | European myelopathy score.tw |
| 41 | EMS.tw |
| 42 | Bournemouth questionnaire.tw |
| 43 | BQ.tw |
| 44 | Cervical spine outcomes questionnaire.tw |
| 45 | CSOQ.tw |
| 46 | Patient specific functional scale.tw |
| 47 | PSFS.tw |
| 48 | World Health Organization Quality of Life Instruments.tw |
| 49 | WHOQOL.tw |
| 50 | Grip and release test.tw |
| 51 | GRT.tw |
| 52 | Grip Dynamometer.tw |
| 53 | Triangle step test.tw |
| 54 | Foot tapping test.tw |
| 55 | 30 m walking test.tw |
| 56 | 30MWT.tw |
| 57 | 10 m walking test.tw |
| 58 | 10MWT.tw |
| 59 | Berg Balance Scale.tw |
| 60 | BBS.tw |
| 61 | GAITRite.tw |
| 62 | 10 second step test.tw |
| 63 | 9 hole peg test.tw |
| 64 | Prolo.tw |
| 65 | Mental component score.tw |
| 66 | MCS.tw |
| 67 | Physical component score.tw |
| 68 | PCS.tw |


| 69 | Hospital anxiety depression scale.tw |
| :---: | :---: |
| 70 | HADS.tw |
| 71 | Global rating of change.tw |
| 72 | GROC.tw |
| 73 | 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 |
| Tools for QOL concept (including pain) concept |  |
| 74 | Exp "Quality of Life"/ or exp "Surveys and Questionnaires"/ |
| 75 | Short Form Health Survey.tw |
| 76 | SF-36.tw |
| 77 | SF-12.tw |
| 78 | EQ-5D.tw |
| 79 | Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire.tw |
| 80 | JOACMEQ.tw |
| 81 | Visual Analogue Scale.tw |
| 82 | VAS.tw |
| 83 | Likert scale.tw |
| 84 | Numeric pain rating scale.tw |
| 85 | NPRS.tw |
| 86 | North American Spine Satisfaction.tw |
| 87 | NASS.tw |
| 88 | 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 or 85 or 86 or 87 |
| Psychometric concept |  |
| 89 | Exp Psychometrics/ |
| 90 | Pyschometr**tw |
| 91 | (clinimetr* or clinometr*).tw. |
| 92 | Outcome assessment*.tw |
| 93 | exp Health Status Indicators/ |
| 94 | Exp "Reproducibility of Results"/ |
| 95 | Reproducib*.tw |
| 96 | Exp Validation Study/ |
| 97 | exp Discriminant Analysis/ |
| 98 | (reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or internal consistency).tw |
| 99 | (cronbach* and (alpha or alphas)).tw. |
| 100 | (item and (correlation* or selection* or reduction*)).tw |

(agreement or precision or imprecision or precise values or test-retest).tw (reliab* and (test or retest)).tw
(stability or interrater or inter-rater or intrarater or intra-rater or intertester or inter-tester or intratester or intra-tester or interobserver or inter-observer or intraobserver or intraobserver or intertechnician or inter-technician or intratechnician or intra-technician or interexaminer or inter-examiner or intraexaminer or intra-examiner or interassay or interassay or intraassay or intra-assay or interindividual or inter-individual or intraindividual or intra-individual or interparticipant or inter-participant or intraparticipant or intra-participant or kappa or kappas or repeatab*).tw
((replicab* or repeated) and (measure or measures or findings or result or results or test or tests)).tw
(generaliza* or generalisa* or concordance).tw
(intraclass and correlation*).tw
Exp Observer Variation/
Observer variation.tw
(multitrait and scaling and (analysis or analyses)).tw
Measurement error*.tw
(item discriminant or interscale correlation* or error or errors or individual variability).tw
(variability and (analysis or values)).tw
(uncertainty and (measurement or measuring)).tw
Exp Diagnostic Errors/
Exp Data accuracy/
Exp Dimensional Measurement Accuracy/
Accuracy.tw
((minimal or minimally or clinical or clinically) and (important or significant or detectable) and (change or difference)).tw

Minimally clinically important difference*.tw
MCID.tw
(small* and (real or detectable) and (change or difference)).tw
(meaningful change or ceiling effect or floor effect or Item response model or IRT or Rasch or Differential item functioning or DIF or computer adaptive testing or item bank or crosscultural equivalence).tw

Exp Bias/ or $\exp$ Selection Bias/
Bias.tw
Exp "Predictive Value of Test"/

12689 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102 or 103 or 104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125

## Combined concepts

12773 or 88
12822 and 126 and 127
EMBASE

## Cervical spine concept

1 exp Cervical Vertebra/ or cervical spine/ or exp Cervical spinal cord/ or cervical.tw DCM concept
2 Exp Spinal Cord Disease/ or Exp Spine Disease/
3 Exp degeneration/
4 degenerat*.tw
$5 \quad 3$ or 4
$6 \quad 2$ and 5
7 Myelopath*.tw
8 Myeloradiculopath*.tw
9 Exp radiculopathy/
10 Radiculopath*.tw
11 Exp Spinal Cord Compression/
12 Exp Posterior Longitudinal Ligament/ and exp ossification/
13 Ossification of the Posterior Longitudinal Ligament.tw
14 OPLL.tw
15 Exp vertebral canal stenosis/
16 Cervical stenosis.tw
17 Exp Cervical Spondylosis/
18 Exp Spondylosis/
19 Spondylosis.tw
20 Spondylotic.tw
21 Exp Cervical myelopathy/
22 Degenerative cervical myelopathy.tw
23 DCM.tw
24 Exp Cervical spondylotic myelopathy/
25 Cervical spondylotic myelopathy.tw
26 CSM.tw
276 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26

281 and 27

| Tools for function concept (neurological/gait/mobility centric) concept |  |
| :--- | :--- |
| 29 | Exp Japanese Orthopaedic Association score/ |
| 30 | Japanese Orthopaedic Association score.tw |
| 31 | JOA.tw |
| 32 | modified JOA.tw |
| 33 | mJOA.tw |
| 34 | Exp "Disabilities of the Arm, Shoulder and Hand (score)"/ |
| 35 | Graded Redefined Assessment of Sensation Strength and Prehension.tw |
| 36 | GRASSP.tw |
| 37 | Quick Disability of the Arm Shoulder and Hand.tw |
| 38 | QuickDASH.tw |
| 39 | Myelopathy Disability Index.tw |
| 40 | MDI.tw |
| 41 | Exp "Nurick (grade)"/ |
| 42 | Nurick score.tw |
| 43 | Neck functional disability scale.tw |
| 44 | NFDS.tw |
| 45 | Exp Neck Disability Index/ |
| 46 | Neck Disability Index.tw |
| 47 | NDI.tw |
| 48 | Cooper myelopathy scale.tw |
| 49 | CMS.tw |
| 50 | European myelopathy score.tw |
| 64 | EMS.tw |
| 64 | Friangle step test.tw |
| 54 | Gournemouth questionnaire.tw |
| 53 | BQ.tw |
| 54 | Cervical spine outcomes questionnaire.tw test.tw |
| 55 | CSOQ.tw |
| 56 | Patient specific functional scale.tw |
| 57 | PSFS.tw |
| 58 | World Health Organization Quality of Life Instruments.tw |


| 65 | 30 m walking test.tw |
| :---: | :---: |
| 66 | 30MWT.tw |
| 67 | 10 m walking test.tw |
| 68 | 10MWT.tw |
| 69 | Berg Balance Scale.tw |
| 70 | BBS.tw |
| 71 | GAITRite.tw |
| 72 | 10 second step test.tw |
| 73 | 9 hole peg test.tw |
| 74 | Prolo.tw |
| 75 | Mental component score.tw |
| 76 | MCS.tw |
| 77 | Physical component score.tw |
| 78 | PCS.tw |
| 79 | Hospital anxiety depression scale.tw |
| 80 | HADS.tw |
| 81 | Global rating of change.tw |
| 82 | GROC.tw |
| 83 | 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 69 or 70 or 71 or 72 or 73 or 74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 |
| Tools for QOL concept (including pain) concept |  |
| 84 | Short Form Health Survey.tw |
| 85 | Exp Short Form 36/ |
| 86 | SF-36.tw |
| 87 | Exp Short Form 12/ |
| 88 | SF-12.tw |
| 89 | Exp "European Quality of Life 5 Dimensions questionnaire"/ |
| 90 | EQ-5D.tw |
| 91 | Exp Japanese Orthopaedic Association Cervical Myelopathy Evaluation/ |
| 92 | Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire.tw |
| 93 | JOACMEQ.tw |
| 94 | Exp visual analog scale/ |
| 95 | Visual Analogue Scale.tw |
| 96 | VAS.tw |
| 97 | Exp Likert scale/ |
| 98 | Likert scale.tw |

Numeric pain rating scale.tw

84 or 85 or 86 or 87 or 88 or 89 or 90 or 91 or 92 or 93 or 94 or 95 or 96 or 97 or 98 or 99 or 100 or 101 or 102

## Psychometric concept

104 Exp Psychometry/
105 Pyschometr*.tw
106 (clinimetr* or clinometr*).tw.
(stability or interrater or inter-rater or intrarater or intra-rater or intertester or inter-tester or intratester or intra-tester or interobserver or inter-observer or intraobserver or intraobserver or intertechnician or inter-technician or intratechnician or intra-technician or interexaminer or inter-examiner or intraexaminer or intra-examiner or interassay or interassay or intraassay or intra-assay or interindividual or inter-individual or intraindividual or intra-individual or interparticipant or inter-participant or intraparticipant or intra-participant or kappa or kappas or repeatab*).tw
NPRS.tw
North American Spine Satisfaction.tw
NASS.tw

Outcome assessment*.tw
exp Health Status Indicator/
Exp Reproducibility/
Reproducib*.tw
Exp Validation Study/
exp Discriminant Analysis/
(reliab* or unreliab* or valid* or coefficient or homogeneity or homogeneous or internal consistency).tw
(cronbach* and (alpha or alphas)).tw.
(item and (correlation* or selection* or reduction*)).tw
(agreement or precision or imprecision or precise values or test-retest).tw
(reliab* and (test or retest)).tw ((replicab* or repeated) and (measure or measures or findings or result or results or test or tests)).tw
(generaliza* or generalisa* or concordance).tw
(intraclass and correlation*).tw
Exp Observer Variation/
Observer variation.tw
(multitrait and scaling and (analysis or analyses)).tw
Measurement error*.tw
(item discriminant or interscale correlation* or error or errors or individual variability).tw

127 (variability and (analysis or values)).tw
128 (uncertainty and (measurement or measuring)).tw
129 Exp Diagnostic Error/
130 Exp Data accuracy/
131 Exp Dimensional Measurement Accuracy/
132 ((minimal or minimally or clinical or clinically) and (important or significant or detectable) and (change or difference)).tw
133 Minimally clinically important difference*.tw
134 MCID.tw
135 (small* and (real or detectable) and (change or difference)).tw
136 (meaningful change or ceiling effect or floor effect or Item response model or IRT or Rasch or Differential item functioning or DIF or computer adaptive testing or item bank or crosscultural equivalence).tw

Exp Bias/ or exp Selection Bias/
138 Bias.tw
139104 or 105 or 106 or 107 or 108 or 109 or 110 or 111 or 112 or 113 or 114 or 115 or 116 or 117 or 118 or 119 or 120 or 121 or 122 or 123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 134 or 135 or 136 or 137 or 138

## Combined concepts

$140 \quad 83$ or 103
14128 and 139 and 140

Supplementary Table 2. Study characteristics

| Study | Country | $\begin{array}{r} \text { Sample } \\ \text { size } \end{array}$ | Psychometric properties | Outcome measures |
| :---: | :---: | :---: | :---: | :---: |
| Auffinger, Lall (1) | United States | 30 | MCID/SCB <br> Measurement error | NDI VAS for pain SF-36 |
| Augusto, Diniz (2) | Brazil | 30 | Cross-cultural validity/Measurement invariance Reliability Responsiveness | $\begin{aligned} & \text { JOA } \\ & \text { NDI } \end{aligned}$ |
| Azimi, Rezaei (3) | Iran | 87 | Cross-cultural validity/Measurement invariance Responsiveness | JOACMEQ |
| Badhiwala, Witiw (4) | Canada | 606 | MCID/SCB | $\begin{aligned} & \text { SF-36 } \\ & \text { mJOA } \\ & \text { Nurick Scale } \\ & \text { NDI } \\ & \hline \end{aligned}$ |
| Bohm, Fehlings (5) | Multicenter/ Global | 601 | Reliability <br> Hypotheses testing for construct validity Responsiveness | ```Walking tests (timed or steps) mJOA Nurick Scale NDI SF-36``` |
| Carreon, Glassman (6) | United States | 505 | MCID/SCB | NDI <br> SF-36 <br> "Numeric rating scale" for pain |
| Chang, Kong (7) | Korea | 108 | Reliability | CT / CTM |
| Chiba, Kato (8) | Japan |  | Reliability | X-rays |
| Chien, Lai (9) | Taiwan | 45 | Responsiveness MCID/SCB | $\begin{aligned} & \text { JOACMEQ } \\ & \text { NDI } \\ & \hline \end{aligned}$ |
| Chiu and Pang (10) | Hong Kong | 72 | Internal consistency <br> Reliability <br> Content validity <br> Hypotheses testing for construct validity <br> Criterion validity <br> Measurement error | $\begin{aligned} & \text { BBS } \\ & \text { mJOA } \end{aligned}$ |


| Responsiveness |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| Fukui, Chiba (11) | Japan | 368 | Content validity | JOACMEQ |
| Fukui, Chiba (12) | Japan | 201 | Reliability | JOACMEQ |
| Goyal, Murphy (13) | United States | 118 | Responsiveness | $\begin{aligned} & \text { NDI } \\ & \text { SF-12 } \end{aligned}$ |
| Gwinn, Iannotti (14) | United States | 20 | Reliability | X-rays Cobb's method |
| Hosono, Sakaura (15) | Japan | 30 | Reliability Criterion validity | Grip-and-release test JOA |
| Hosono, Takenaka (16) | Japan | 48 | Responsiveness | Grip-and-release test JOA |
| Kang, Lee (17) | Korea | 82 | Reliability | MRI (not DTI) |
| Kato, Oshima (18) | Japan | 92 | Measurement error <br> Hypotheses testing for construct validity Responsiveness | $\begin{aligned} & \text { JOA } \\ & \text { mJOA } \\ & \text { JOACMEQ } \\ & \text { NDI } \\ & \text { SF-12 } \\ & \hline \end{aligned}$ |
| Kato, Oshima (19) | Japan | 101 | Measurement error Criterion validity MCID/SCB | JOA <br> Likert scale |
| Kato, Oshima (20) | Japan | 101 | Measurement error Criterion validity MCID/SCB | $\begin{aligned} & \hline \text { JOACMEQ } \\ & \text { NDI } \\ & \text { EQ-5D } \\ & \text { SF-36 } \\ & \text { Likert scale } \end{aligned}$ |
| King and Roberts (21) | United States | 88 | Internal consistency | SF-36 |
| Ko, Choi (22) | Korea | 357 | Reliability | MRI (not DTI) |
| Kopjar, Tetreault (23) | USA | 277 | Responsiveness <br> Hypotheses testing for construct validity Internal consistency | mJOA <br> Nurick Scale <br> NDI <br> SF-36 <br> Walking tests (timed or steps) |
| Latimer, Haden (24) | England | 70 | Responsiveness | $\begin{aligned} & \text { SF-36 } \\ & \text { NDI } \end{aligned}$ |


|  |  |  |  | VAS for pain MDI |
| :---: | :---: | :---: | :---: | :---: |
| Longo, Berton (25) | Italy | 75 | Cross-cultural validity/Measurement invariance Reliability Internal consistency Hypotheses testing for construct validity Responsiveness Criterion validity | mJOA <br> Nurick Scale NDI SF-36 |
| Lubelski, Alvin (26) | United States | 119 | Hypotheses testing for construct validity Responsiveness Criterion validity | mJOA <br> Nurick Scale <br> EQ-5D |
| Mihara, Kondo (27) | Japan | 270 | Hypotheses testing for construct validity | Grip-and-release test Triangle step test |
| Nakamoto, Oshima (28) | Japan | 94 | Internal consistency Hypotheses testing for construct validity Criterion validity |  |
| Nakashima, Yukawa (29) | Japan | 101 | Hypotheses testing for construct validity |  |
| Nicholson, Millhouse (30) | United States | 235 | Hypotheses testing for construct validity | $\begin{aligned} & \text { MRI (not DTI) } \\ & \text { mJOA } \\ & \text { NDI } \\ & \text { SF-12 } \end{aligned}$ <br> "Numeric rating scale" for pain Isihara's Cervical Curvature Index |
| Nikaido, Kikuchi (31) | Japan | 87 | Hypotheses testing for construct validity) | $\begin{aligned} & \text { JOACMEQ } \\ & \text { SF-36 } \end{aligned}$ |
| Numasawa, Ono (32) | Japan | 126 | Hypotheses testing for construct validity Responsiveness Reliability | JOA <br> Foot tapping test Grip-and-release test |
| Olindo, Signate (33) | France | 40 | Reliability | 9-Hole peg test <br> MRI (not DTI) <br> Nurick Scale <br> mJOA <br> Walking tests (timed or steps) |


| Park, Kim (34) | Korea | 100 | Reliability | MRI (not DTI) |
| :--- | :--- | ---: | :--- | :--- |
| Pratali, Smith (35) | Brazil |  | Cross-cultural validity | mJOA |
| Pratali, Smith (36) | Brazil | 55 | Reliability | mJOA |
| Rhee, Shi (37) | United States | 100 | Criterion validity | RJOA |
|  |  |  | Reliability |  |
| Content validity |  |  |  |  |


|  |  |  | Responsiveness MCID/SCB | Nurick Scale |
| :---: | :---: | :---: | :---: | :---: |
| Wada, Fukui (47) | Japan | 137 | Responsiveness | $\begin{aligned} & \text { JOACMEQ } \\ & \text { JOA } \\ & \text { 10-s step test } \end{aligned}$ |
| Witayakom, Paholpak (48) | Thailand | 70 | Cross-cultural validity/Measurement invariance <br> Reliability <br> Internal consistency <br> Hypotheses testing for construct validity | $\begin{aligned} & \text { JOACMEQ } \\ & \text { SF-36 } \end{aligned}$ |
| Yonenobu, Abumi (49) | Japan | 29 | Reliability | JOA |
| Yukawa, Kato (50) | Japan | 163 | Hypotheses testing for construct validity Reliability Criterion validity | $\begin{aligned} & \text { 10-s step test } \\ & \text { JOA } \\ & \text { Grip-and-release test } \end{aligned}$ |
| Zhang, Zhou (51) | China | 142 | Internal consistency Responsiveness MCID/SCB | $\begin{aligned} & \text { SF-36 } \\ & \text { mJOA } \end{aligned}$ |
| Zhou, Zhang (52) | China | 113 | MCID/SCB <br> Measurement error | $\begin{aligned} & \hline \text { mJOA } \\ & \text { SF-36 } \end{aligned}$ |

Supplementary Table 3. Interpretability (i.e., MCID and SCB).

| Instrument | Result summary | Overall rating |
| :---: | :---: | :---: |
| EQ-5D | MCID: 0.05; total sample size: 101 | Sufficient |
| JOA | MCID: 2.5; total sample size: 101 | Sufficient |
| JOACMEQ |  |  |
| Bladder function | MCID: 6.0; total sample size: 78 | Sufficient |
| Cervical <br> spine <br> function | MCID: 2.5; total sample size: 179 | Sufficient |
| Lower extremity function | MCID range 2.5-9.4; total sample size: 179 | Sufficient |
| QOL | MCID range 8.5-9.5; total sample size: 179 | Sufficient |
| Upper extremity function | MCID range 2.5-13.0; total sample size: 179 | Sufficient |
| mJOA | MCID range 1.3-3.1; total sample size: 868 | Sufficient |
|  | SCB: 14; total sample size: 35 | Indeterminate |
| NDI | MCID range 5-13; total sample size: 108 | Sufficient |
|  | SCB range 9.5-36; total sample size: 65 | Indeterminate |
| Pain, "Numeric rating scale" (Arm pain) | MCID: 2.5; total sample size: 30 <br> SCB: 3.5; total sample <br> size: 30 | Indeterminate |
| Pain, "Numeric rating scale" (Neck pain) | MCID: 2.5; total sample <br> size: 30 <br> SCB: 3.5; total sample <br> size: 30 | Indeterminate |


| MCS | SCB: 51.5; total sample size: 35 | Indeterminate |
| :---: | :---: | :---: |
| PCS | SCB: 30.1; total sample size: 35 | Indeterminate |
| SF-36 |  |  |
| MCS | MCID range 3.0-7.4; total sample size: 749 | Sufficient |
| PCS | "MCID range 3.9-9.6; <br> total sample size: 890 <br> SCB: 16; total sample <br> size: 30" | Sufficient |
| VAS for pain | MCID range 0.4-2.7; total sample size: 30 | Sufficient |
|  | SCB: 1.1; total sample size: 30 | Indeterminate |

## Supplementary Table 4. Feasibility assessment.

| Tool | Time (min) | Equipment | Training | License | Money | Ease of administration | Overall assessment |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 10-s step test | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| 30MWT | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| 9-Hole peg test | 5 | Yes | No | No | No | Barriers | Barriers |
| Berg Balance Scale | >15 | Yes | Yes | No | No | Barriers | Barriers |
| Cobb's method (C2-C7) | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| CT (Tsuyama's classification, 2D \& |  |  |  |  |  |  |  |
| 3D) | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| CT <br> (Tsuyama's classification, lateral |  |  |  |  |  |  |  |
| + axial) | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| EQ-5D | 5 | Minimal | No | Yes | Yes | Minimal barriers | Minimal barriers |
| European |  |  |  |  |  |  |  |
| Myelopathy Scale | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| Foot tapping test | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| Grip-and-release test Isihara's Cervical | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| Curvature Index | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| JOA | 5 | No | No | No | No | No barriers | No barriers |


| JOACMEQ | $5-15$ | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| :--- | ---: | :--- | :--- | :--- | :--- | :--- | :--- |
| MDI |  |  |  |  |  |  |  |
| mJOA |  |  |  |  |  |  |  |
| MRI |  |  |  |  |  |  |  |
| (Depiction of |  |  |  |  |  |  |  |
| intramedullary |  |  |  |  |  |  |  |
| hyperintensity at |  |  |  |  |  |  |  |
| eight cervical disc |  |  |  |  |  |  |  |
| levels, T2W, 1.5-T or |  |  |  |  |  |  |  |
| 3-T) | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |

Arm pain score

|  | 5 | No | No | No | No | No barriers | No barriers |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Neck pain score |  |  |  |  |  |  |  |
|  | 5 | No | No | No | No | No barriers | No barriers |
| QuickDASH | 5 | Minimal | No | Yes | Yes | Minimal barriers | Barriers |
| Ranawat |  |  |  |  |  |  |  |
| disease severity | 5 | No | No | No | No | No barriers | No barriers |
| SF-12 | 5 | Minimal | No | Yes | Yes | Minimal barriers | Barriers |
| SF-36 | 5-15 | Minimal | No | Yes | Yes | Minimal barriers | Barriers |
| Triangle step test | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| VAS for pain | 5 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| WHOQOL-Bref | 5-15 | Minimal | No | No | No | Minimal barriers | Minimal barriers |
| X-rays |  |  |  |  |  |  |  |
| (Computer-assisted |  |  |  |  |  |  |  |
| length \& thickness) | 5-15 | Minimal | No | No | No | Minimal barriers | Minimal barriers |

Supplementary Table 5. Content validity.

| Instrument | Result summary | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| BBS | Patient comprehensibility: Item discrimination index >0.589 | Indeterminate | Very low |
| JOACMEQ | Patient comprehensibility: <br> "No questions elicited no answer or "I am not sure" in more than $5 \%$ of patients" | Indeterminate | Very low |
| P-mJOA | Patient comprehensibility: <br> "In patients preferring to complete the mJOA them- selves, the most popular answers were: "ease of answering the questions" ( $n=33$ ), "understanding of the questions" ( $n=17$ )" | Indeterminate | Very low |

## Supplementary Table 6. Internal consistency.

| Instrument | Result summary | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| BBS | Cronbach's alpha range 0.95-0.98; consistent; total sample size: 72 | Indeterminate | Moderate |
| European <br> Myelopathy Scale | Cronbach's alpha: 0.68; consistent; total sample size: 100 | Indeterminate | Low |
| JOA | Cronbach's alpha: 0.72; consistent; total sample size: 100 | Indeterminate | Low |
| JOACMEQ | Cronbach's alpha: 0.91; total sample size: 70 | Indeterminate | Moderate |
| Bladder <br> function | Cronbach's alpha range 0.77-0.78; consistent; total sample size: 157 | Indeterminate | High |
| Cervical spine function | Cronbach's alpha range 0.75-0.88; consistent; total sample size: 157 | Indeterminate | High |
| QOL | Cronbach's alpha range 0.80-0.86; consistent; total sample size: 157 | Indeterminate | High |
| Upper <br> extremity <br> function | Cronbach's alpha range 0.72-0.74; consistent; total sample size: 157 | Indeterminate | High |
| MDI | Cronbach's alpha: 0.92; consistent; total sample size: 100 | Indeterminate | Low |
| mJOA | Cronbach's alpha range 0.60-0.63; consistent; total sample size: 352 | Indeterminate | High |
| QuickDASH | Cronbach's alpha: 0.94; consistent; total sample size: 94 | Indeterminate | Very low |
| SF-12 | Cronbach's alpha: 0.77; consistent; total sample size: 105 | Indeterminate | n/a |


| SF-36 | Cronbach's alpha range | Indeterminate | $\mathrm{n} / \mathrm{a}$ |
| :--- | :--- | :--- | :--- |
|  | $0.79-0.93$; consistent; |  |  |
|  | total sample size: 473 |  | $\mathrm{n} / \mathrm{a}$ |
| WHOQOL-Bref | Cronbach's alpha range | Indeterminate |  |
|  | $0.86-0.87 ;$ consistent; |  |  |
|  | total sample size: 38 |  |  |

$\mathrm{n} / \mathrm{a}=$ No info available

Supplementary Table 7. Cross-cultural validity.

| Instrument | Result summary | Overall rating | Quality of evidence |
| :--- | :--- | :--- | :---: |
| JOA | Forward-backward | Indeterminate | Very low |
|  | translation [Brazilian |  |  |
|  | Portuguese] |  |  |
|  | Comprehension rate: |  |  |
|  | $>81.2 \%$ |  |  |
|  | Forward-backward | Indeterminate | Very low |
|  | translation [Persian and |  |  |
|  | Thai] |  |  |
|  | No info available |  |  |
|  | Forward-backward | Indeterminate | Very low |
|  | translation [Brazilian |  |  |
|  | Portuguese and Italian] |  |  |
|  | No info available |  |  |
|  |  |  |  |

## Supplementary Table 8. Reliability.

| Instrument | Result summary | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| 10-s step test | Test-retest stability: <br> Spearman's rank correlation: 0.89; total sample size: 163 | Indeterminate | Low |
| 30MWT | Test-retest stability: <br> Pearson's correlation range 0.89-1.00; total sample size: 16 | Indeterminate | Very low |
| 9-Hole peg test | Intra-observer reliability: ICC range 0.97-0.98; consistent; total sample size: 41 Inter-observer reliability: ICC range 0.97-0.99; consistent; total sample size: 41 | Sufficient | Very low |
| BBS* | Test-retest stability: <br> ICC: 0.99; total sample <br> size: 32 <br> Inter-observer reliability: <br> ICC: 0.99; total sample <br> size: 32 | Sufficient | Very low |
|  | Test-retest stability: <br> Kappa: 0.67; total sample size: 32 Inter-observer reliability: Kappa: 0.43; total sample size: 32 | Insufficient | Very low |
| Cobb's method | Intra-observer reliability: ICC: 0.84 ; total sample size: 20 Inter-observer reliability: ICC: 0.77; total sample size: 20 | Sufficient | Very low |
| CT | Intra-observer reliability: | Sufficient | Moderate |


| (Tsuyama's classification, 2D \& 3D) | Kappa range 0.85- |  |  |
| :---: | :---: | :---: | :---: |
|  | 0.86; consistent; total |  |  |
|  | sample size: 108 |  |  |
|  | Inter-observer reliability: |  |  |
|  | Kappa range 0.71- |  |  |
|  | 0.76 ; consistent; total sample size 108 |  |  |
| CT <br> (Tsuyama's <br> classification, lateral + axial) | Intra-observer reliability: | Insufficient | Moderate |
|  | Kappa: 0.67; total |  |  |
|  | sample size: 108 |  |  |
|  | Inter-observer reliability: |  |  |
|  | Kappa: 0.51; total sample size: 108 |  |  |
| Foot tapping test | Test-retest stability: | Indeterminate | Low |
|  | Pearson's correlation |  |  |
|  | range 0.90-0.93; total |  |  |
|  | sample size: 126 |  |  |
| Grip-and-release test | Inter-observer reliability: ICC. 0.99; total sample | Sufficient | Very low |
|  | size: 30 |  |  |
| JOA | Inter-observer reliability: | Sufficient | Very low |
|  | ICC: 0.81; total sample |  |  |
|  | size: 29 |  |  |
| Bladder function |  | Insufficient | Very low |
|  | Kappa: 0.64; total |  |  |
|  | sample size: 29 |  |  |
|  | Inter-observer reliability: |  |  |
|  | Kappa: 0.47; total |  |  |
|  | sample size: 29 |  |  |
| Motor function of fingers | Intra-observer reliability: | Insufficient | Very low |
|  | Kappa: 0.68; total |  |  |
|  | sample size: 29 |  |  |
|  | Inter-observer reliability: |  |  |
|  | Kappa: 0.53; total |  |  |
|  | sample size: 29 |  |  |
| Motor <br> function of | Intra-observer reliability: | Insufficient | Very low |
|  | Kappa: 0.50; total |  |  |
|  | sample size: 29 |  |  |


| shoulder and elbow | Inter-observer reliability: <br> Kappa: 0.31; total sample size: 29 |  |  |
| :---: | :---: | :---: | :---: |
| Motor <br> function of Iower extremity | Intra-observer reliability: <br> Kappa: 0.55; total <br> sample size: 29 <br> Inter-observer reliability: <br> Kappa: 0.49; total <br> sample size: 29 | Insufficient | Very low |
| Sensory function of lower extremity | Intra-observer reliability: <br> Kappa: 0.44; total <br> sample size: 29 <br> Inter-observer reliability: <br> Kappa: 0.34; total <br> sample size: 29 | Insufficient | Very low |
| Sensory function of trunk | Intra-observer reliability: <br> Kappa: 0.54; total <br> sample size: 29 <br> Inter-observer reliability: <br> Kappa: 0.58; total <br> sample size: 29 | Insufficient | Very low |
| Sensory function of upper extremity | Intra-observer reliability: <br> Kappa: 0.51; total <br> sample size: 29 <br> Inter-observer reliability: <br> Kappa: 0.42; total <br> sample size: 29 | Insufficient | Very low |
| JOACMEQ |  |  |  |
| Bladder function | Test-retest stability: ICC: 0.62; total sample size: 70 | Insufficient | Very low |
| Cervical <br> spine <br> function | Test-retest stability: ICC: 0.63; total sample size: 70 | Insufficient | Very low |
| Lower extremity function | Test-retest stability: <br> ICC: 0.93; total sample <br> size: 70 | Sufficient | Very low |
| QOL | Test-retest stability: | Sufficient | Very low |


|  | ICC: 0.83; total sample size: 70 |  |  |
| :---: | :---: | :---: | :---: |
| Upper extremity function | Test-retest stability: ICC: 0.93; total sample size: 70 | Sufficient | Very low |
| mJOA | Test-retest stability: Spearman's rank correlation: 0.91; total sample size: 75 | Indeterminate | Very low |
|  | Intra-observer reliability: <br> ICC: 0.87 ; total sample <br> size: 55 | Sufficient | Very low |
|  | Inter-observer reliability: <br> ICC: 0.97; total sample <br> size: 55 <br> Kappa: 0.80; total <br> sample size: 75 | Sufficient | Low |
| Motor dysfunction of lower extremities | Inter-observer reliability: <br> ICC: 0.73; total sample <br> size: 75 | Sufficient | Low |
| Motor <br> dysfunction <br> of upper <br> extremities | Inter-observer reliability: <br> ICC: 0.77; total sample <br> size: 75 | Sufficient | Low |
| Sensory dysfunction of sphincter dysfunction | Inter-observer reliability: ICC: 0.78; total sample size: 75 | Sufficient | Low |
| Sensory dysfunction of upper extremities | Inter-observer reliability: <br> ICC: 0.93; total sample <br> size: 75 | Sufficient | Low |
| MRI <br> (Depiction of intramedullary hyperintensity at eight cervical disc | Inter-observer reliability: <br> Kendall's W range <br> 0.72-0.78; total <br> sample size: 79 | Indeterminate | Very low |


| levels, T2W, 1.5-T or 3-T) |  |  |  |
| :---: | :---: | :---: | :---: |
| MRI <br> (Kang's <br> classification, 1.5-T <br> or 3-T) | Intra-observer reliability: <br> Kappa: 0.67; total sample size: 439 ICC: 0.77 , total sample size: 82 <br> Inter-observer reliability: <br> Kappa range 0.60- <br> 0.93 ; total sample size: <br> 539 <br> ICC range 0.74-0.75; <br> total sample size: 82 | Inconsistent | n/a |
| MRI <br> (Muhle's classification, $1.5-\mathrm{T}$ ) | Intra-observer reliability: <br> Kappa: 0.72; total sample size: 357 Inter-observer reliability: Kappa range 0.61; total sample size: 357 | Inconsistent | n/a |
| MRI <br> (Vaccaro's classification, $1.5-\mathrm{T}$ ) | Intra-observer reliability: <br> Kappa: 0.71; total sample size: 357 Inter-observer reliability: Kappa range 0.69; total sample size: 357 | Sufficient | Moderate |
| P-mJOA <br> Motor <br> dysfunction <br> of lower extremities | Inter-observer reliability: <br> Kappa: 0.61; total sample size: 755 | Insufficient | Moderate |
| Motor dysfunction of upper extremities | Inter-observer reliability: <br> Kappa: 0.66; total sample size: 755 | Insufficient | Moderate |
| Sensory dysfunction of sphincter dysfunction | Inter-observer reliability: <br> Kappa: 0.55; total sample size: 755 | Insufficient | Moderate |


| Sensory dysfunction of upper extremities | Inter-observer reliability: <br> Kappa: 0.55; total <br> sample size: 755 | Insufficient | Moderate |
| :---: | :---: | :---: | :---: |
| X-rays <br> (Computer-assisted measurement of length) | Intra-observer reliability: ICC: 0.94; total sample size: 9 <br> Inter-observer reliability: ICC: 0.93; total sample size: 9 | Sufficient | Very low |
| X-rays <br> (Computer-assisted measurement of thickness) | Intra-observer reliability: ICC: 0.96; total sample size: 9 Inter-observer reliability: ICC: 0.97; total sample size: 9 | Sufficient | Very low |

[^0]
## Supplementary Table 9. Measurement error.

| Instrument | Result summary | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| BBS | MDC or SDC <br> Distribution: 1.5; total sample size: 32 | Indeterminate | n/a |
| EQ-5D | MDC or SDC <br> Distribution: 0.13; total sample size: 101 <br> Anchor: 0.04; total sample size: 101 | Inconsistent | n/a |
| JOA | MDC or SDC <br> Distribution: 1.0; total <br> sample size: 101 <br> Anchor: 2.5; total sample size: 101 LOA <br> 1.2 (-1.2, 3.6); total sample size: 92 | Sufficient | Very low |
| JOACMEQ |  |  |  |
| Bladder function | MDC or SDC <br> Distribution: 7.7; total sample size: 101 | Insufficient | Very low |
| Cervical <br> spine <br> function | MDC or SDC <br> Distribution: 12.9; total <br> sample size: 101 <br> Anchor: 12.5; total <br> sample size: 101 | Insufficient | Very low |
| Lower <br> extremity <br> function | MDC or SDC <br> Distribution: 7.3; total <br> sample size: 101 <br> Anchor: 9.4; total <br> sample size: 101 | Inconsistent | n/a |
| QOL | MDC or SDC <br> Distribution: 6.6; total sample size: 101 Anchor: 8.5; total sample size: 101 | Sufficient | Very low |


| Upper extremity function | MDC or SDC <br> Distribution: 9.5; total sample size: 101 Anchor: 6.1; total sample size: 101 | Sufficient | Very low |
| :---: | :---: | :---: | :---: |
| mJOA | MDC or SDC <br> Distribution: 2.1; total sample size: 113 | Inconsistent | Very low |
|  | MCID range; total sample size: 868 <br> Distribution: 1.2-1.4 | Sufficient | High |
| NDI | MDC or SDC <br> Distribution: 6.2\%; <br> total sample size: 101 <br> Anchor: 5.2\%; total <br> sample size: 101 | Insufficient | Very low |
| SF-36 |  |  |  |
| MCS | MDC or SDC <br> Distribution: 3.3-5.7; <br> total sample size: 244 | Inconsistent | n/a |
|  | MCID; total sample size: 748 <br> Distribution: 3.4-6.8 | Inconsistent | n/a |
| PCS | MDC or SDC <br> Distribution: 5.2-5.7; <br> total sample size: 214 <br> Anchor: 4.9; total sample size: 101 | Inconsistent | n/a |
|  | MCID range; total sample size: 861 <br> Distribution: 2.9-5.5 <br> MCID; total sample size: 51 <br> Distribution: 10 | Inconsistent | n/a |
| VAS for pain | MDC or SDC <br> Distribution: 3.1; total sample size: 30 | Insufficient | Very low |


|  | MCID range 24.0-30.0; total sample size: 51 | Insufficient | Very low |
| :---: | :---: | :---: | :---: |
| WHOQOL-Bref |  |  |  |
| PH | MCID <br> Distribution: 8.2; total sample size: 38 | Indeterminate | n/a |
| PS | MCID <br> Distribution: 7.9; total sample size: 38 | Indeterminate | n/a |
| SR | MCID <br> Distribution: 8.0; total sample size: 38 | Indeterminate | n/a |
| EN | MCID <br> Distribution: 5.6; total sample size: 38 | Indeterminate | n/a |
| PF | MCID <br> Distribution: 10.5; total sample size: 38 | Indeterminate | n/a |
| RP | MCID <br> Distribution: 17.2; total sample size: 38 | Indeterminate | n/a |
| BP | MCID <br> Distribution: 13.2; total sample size: 38 | Indeterminate | n/a |
| GH | MCID <br> Distribution: 12.3; total sample size: 38 | Indeterminate | n/a |
| VT | MCID <br> Distribution: 10.8; total sample size: 38 | Indeterminate | n/a |
| SF | MCID <br> Distribution: 13.6; total sample size: 38 | Indeterminate | n/a |
| RE | MCID <br> Distribution: 18.0; total sample size: 38 | Indeterminate | n/a |
| MH | MCID | Indeterminate | n/a |

Distribution: 11.2; total
sample size: 38
$\mathrm{n} / \mathrm{a}=$ No info available

## Supplementary Table 10. Criterion validity.

| Instrument | Result summary* | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| 10-s step test | JOA <br> Spearman's rank correlation: 0.66; total sample size: 163 | Insufficient | High |
| BBS | $\begin{aligned} & \text { mJOA } \\ & \text { AUC range } 0.88-0.94 ; \\ & \text { total sample size: } 31 \end{aligned}$ | Sufficient | Low |
| Foot tapping test | JOA <br> Pearson's correlation: <br> 0.66 ; total sample size: <br> 126 <br> JOA MFLE <br> Pearson's correlation: <br> 0.70 ; total sample size: <br> 126 | Insufficient | High |
| Grip-and-release test | JOA <br> Pearson's correlation: <br> 0.72 ; total sample size: <br> 30 | Sufficient | Low |
| JOA | Likert scale, "Health transition question" <br> AUC: 0.59; total sample size: 101 <br> Likert scale, "Patient satisfaction question" AUC: 0.62; total sample size: 101 | Insufficient | Very low |
| JOACMEQ |  |  |  |
| Cervical spine function | Likert scale, "Health transition question" <br> AUC: 0.58; total sample size: 101 <br> Likert scale, "Patient satisfaction question" | Insufficient | Very low |


|  | AUC: 0.58; total sample size: 101 |  |  |
| :---: | :---: | :---: | :---: |
| Upper extremity function | Likert scale, "Health transition question" <br> AUC: 0.66; total sample size: 101 <br> Likert scale, "Patient satisfaction question" <br> AUC: 0.65; total sample size: 101 | Insufficient | Very low |
| Lower extremity function | Likert scale, "Health transition question" <br> AUC: 0.61; total sample size: 101 <br> Likert scale, "Patient satisfaction question" <br> AUC: 0.66; total sample size: 101 | Insufficient | Very low |
| QOL | Likert scale, "Health transition question" <br> AUC: 0.70; total sample size: 101 <br> Likert scale, "Patient satisfaction question" AUC: 0.66; total sample size: 101 | Insufficient | Very low |
| mJOA | Nurick scale [convergent] <br> Spearman's rank correlation: -0.41 ; tota sample size: 119 <br> Pearson's correlation range: -0.62 to -0.63 ; total sample size: 352 | Sufficient | High |
| Motor dysfunction of upper extremities | Nurick scale [convergent] <br> Pearson's correlation range -0.42 to -0.42 ; total sample size: 352 | Insufficient | High |


| Motor dysfunction of lower extremities | Nurick scale [convergent] <br> Pearson's correlation: <br> -0.65 to -0.68 ; total <br> sample size: 352 | Sufficient | High |
| :---: | :---: | :---: | :---: |
| Sensory dysfunction of upper extremities | Nurick scale [convergent] <br> Pearson's correlation: <br> -0.23 ; total sample <br> size: 277 | Insufficient | High |
| Sensory dysfunction of sphincter dysfunction | Nurick scale [convergent] <br> Pearson's correlation: <br> -0.25 ; total sample <br> size: 277 | Insufficient | High |
| NDI | Likert scale, "Health transition question" <br> AUC: 0.66; total sample size: 101 <br> Likert scale, "Patient satisfaction question" AUC: 0.75; total sample size: 101 | Inconsistent | n/a |
| P-mJOA | mJOA <br> Spearman's rank correlation: 0.83 ; total sample size: 755 | Sufficient | High |
| QuickDASH | JOA MFSE <br> Spearman's rank correlation: -0.50 ; total sample size: 94 JOA SFUE <br> Spearman's rank correlation: -0.32 ; total sample size: 94 | Insufficient | Moderate |
| SF-36 |  |  |  |
| PCS | Likert scale, "Health transition question" <br> AUC: 0.67; total sample size: 101 | Insufficient | Very low |


|  | Likert scale, "Patient satisfaction question" AUC: 0.69; total sample size: 101 |  |  |
| :---: | :---: | :---: | :---: |
| WHOQOL-Bref |  |  |  |
| PH | SF-36 PCS <br> Pearson's correlation: <br> 0.51 ; total sample size: <br> 38 <br> SF-36 MCS <br> Pearson's correlation: <br> 0.30 ; total sample size: <br> 38 | Inconsistent | n/a |
| PS | SF-36 PCS <br> Pearson's correlation: <br> 0.34 ; total sample size: <br> 38 <br> SF-36 MCS <br> Pearson's correlation: <br> 0.23 ; total sample size: <br> 38 | Insufficient | Low |
| SR | SF-36 PCS <br> Pearson's correlation: <br> 0.35 ; total sample size: <br> 38 <br> SF-36 MCS <br> Pearson's correlation: <br> 0.28 ; total sample size: <br> 38 | Insufficient | Low |
| EN | SF-36 PCS <br> Pearson's correlation: <br> 0.05 ; total sample size: <br> 38 <br> SF-36 MCS <br> Pearson's correlation: <br> 0.03 ; total sample size: <br> 38 | Insufficient | Low |

n/a = No info available
*Instruments listed are comparators

## Supplementary Table 11. Construct validity.

| Instrument | Result summary* | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| 10-s step test | Grip-and-release test [convergent] <br> Spearman's rank correlation: 0.53 ; total sample size: 163 | Sufficient | Moderate |
| 30MWT | mJOA [convergent] <br> Pearson's correlation: <br> -0.44; total sample <br> size: 16 <br> MDI [convergent] <br> Spearman's rank correlation: 0.65 ; total sample size: 41 <br> Nurick scale [convergent] <br> Pearson's correlation: <br> 0.50 ; total sample size: <br> 16 <br> Spearman's rank correlation: 0.61; total sample size: 41 | Sufficient | Moderate |
|  | NDI <br> Pearson's correlation: <br> 0.21 ; total sample size: <br> 16 | Sufficient | Low |
|  | SF-36 PCS <br> Pearson's correlation: -0.35 ; total sample <br> size: 16 | Sufficient | Low |
|  | SF-36 MCS <br> Pearson's correlation: <br> -0.20; total sample <br> size: 16 | Sufficient | Low |
| BBS | mJOA [convergent] <br> Spearman's rank <br> correlation: 0.81; total sample size: 72 | Sufficient | Moderate |


| EQ-5D | mJOA | Insufficient | High |
| :---: | :---: | :---: | :---: |
|  | AUC: 0.68; total sample size: 119 |  |  |
|  | Nurick scale |  |  |
|  | AUC: 0.61; total sample size: 119 |  |  |
| Foot tapping test | Grip-and-release test [convergent] | Sufficient | High |
|  | Pearson's correlation: |  |  |
|  | 0.58 ; total sample size: |  |  |
|  | 126 |  |  |
| Isihara's Cervical | mJOA | Sufficient | High |
| Curvature Index | Pearson's correlation: |  |  |
|  | 0.04 ; total sample size: |  |  |
|  | 235 |  |  |
|  | SF-12 PCS | Sufficient | High |
|  | Pearson's correlation: |  |  |
|  | 0.06 ; total sample size: |  |  |
|  | 235 |  |  |
|  | SF-12 MCS |  |  |
|  | Pearson's correlation: |  |  |
|  | 0.11 ; total sample size: |  |  |
|  | 235 |  |  |
|  | Pain, "Numeric rating <br> scale" (Arm pain score) | Sufficient | High |
|  | Pearson's correlation: |  |  |
|  | -0.28 ; total sample |  |  |
|  | size: 235 |  |  |
|  | Pain, "Numeric rating <br> scale" (Neck pain scores) |  |  |
|  | Pearson's correlation: |  |  |
|  | -0.27 ; total sample |  |  |
|  | size: 235 |  |  |
|  | NDI |  |  |
|  | Pearson's correlation: |  |  |
|  | -0.10; total sample |  |  |
|  | size: 235 |  |  |
| JOA | mJOA [convergent] | Sufficient | Low |


|  | Spearman's rank correlation: 0.87 ; total sample size: 92 |  |  |
| :---: | :---: | :---: | :---: |
|  | JOACMEQ QOL [convergent] <br> Spearman's rank correlation: 0.41; total sample size: 92 | Sufficient | Low |
|  | SF-12 PCS <br> Spearman's rank correlation: 0.50; total sample size: 92 | Sufficient | Low |
|  | SF-12 MCS <br> Spearman's rank correlation: -0.05; total sample size: 92 | Sufficient | Low |
|  | NDI <br> Spearman's rank correlation range 0.50 to -0.76 ; total sample size: 122 | Sufficient | Moderate |
| JOACMEQ |  |  |  |
| QOL | NDI <br> Spearman's rank <br> correlation: -0.66; <br> total sample size: 92 | Sufficient | Low |
| QOL | SF-12 PCS <br> Spearman's rank correlation: 0.29; total sample size: 92 <br> SF-12 MCS <br> Spearman's rank correlation: 0.40; total sample size: 92 | Insufficient | Low |
| MDI | Nurick scale [convergent] <br> Spearman's rank correlation: 0.66; total sample size: 41 | Sufficient | Low |


| mJOA | 30MWT [convergent] <br> Pearson's correlation: <br> -0.38; total sample <br> size: 193 | Insufficient | High |
| :---: | :---: | :---: | :---: |
|  | JOACMEQ QOL [convergent] <br> Spearman's rank correlation: 0.41; total sample size: 92 | Insufficient | Low |
|  | EQ-5D <br> Spearman's rank correlation: 0.42; total sample size: 119 | Insufficient | High |
|  | SF-36 PCS <br> Pearson's correlation range: 0.30-0.30; total sample size: 338 SF-12 PCS <br> Spearman's rank correlation: 0.47; total sample size: 92 | Sufficient | High |
|  | SF-36 MCS <br> Pearson's correlation: <br> 0.25-0.25; total <br> sample size: 338 <br> SF-12 MCS <br> Spearman's rank correlation: 0.03; total sample size: 92 | Sufficient | High |
|  | NDI <br> Spearman's rank correlation: -0.51; total sample size: 92 <br> Pearson's correlation rage -0.33 to -0.34 ; total sample size: 336 | Sufficient | High |
| Motor dysfunction | 30MWT [convergent] | Insufficient | High |


| of lower extremities | Pearson's correlation: -0.43 ; total sample size: 193 |  |  |
| :---: | :---: | :---: | :---: |
|  | SF-36 PCS <br> Pearson's correlation range: 0.31-0.50; total sample size: 338 | Sufficient | High |
|  | SF-36 MCS <br> Pearson's correlation: <br> 0.21 ; total sample size: <br> 268 | Sufficient | High |
|  | NDI <br> Pearson's correlation: -0.31; total sample size: 261 | Sufficient | High |
| Motor dysfunction of upper extremities | 30MWT [convergent] <br> Pearson's correlation: <br> -0.21; total sample <br> size: 193 | Insufficient | High |
|  | SF-36 PCS <br> Pearson's correlation: <br> 0.22 ; total sample size: $268$ | Insufficient | High |
|  | SF-36 MCS <br> Pearson's correlation: <br> 0.20 ; total sample size: <br> 268 | Sufficient | High |
|  | NDI <br> Pearson's correlation: -0.24; total sample size: 261 | Sufficient | High |
| Sensory dysfunction of sphincter dysfunction | 30MWT [convergent] <br> Pearson's correlation: <br> -0.23; total sample <br> size: 193 | Insufficient | High |
|  | SF-36 PCS | Sufficient | High |



\begin{tabular}{|c|c|c|c|}
\hline \& Pearson's correlation: -0.40 ; total sample size: 235 \& \& \\
\hline \& \begin{tabular}{l}
Pain, "Numeric rating scale" (Arm pain score) \\
Pearson's correlation: \\
0.68 ; total sample size: \\
235 \\
Pain, "Numeric rating scale" (Neck pain scores) \\
Pearson's correlation: \\
0.64 ; total sample size: \\
235
\end{tabular} \& Sufficient \& High \\
\hline Nurick scale \& \begin{tabular}{l}
EQ-5D \\
Spearman's rank correlation: -0.28 ; total sample size: 119
\end{tabular} \& Sufficient \& High \\
\hline Pain, "Numeric rating scale" (Arm pain scores) \& \begin{tabular}{l}
mJOA \\
Pearson's correlation: \\
-0.19; total sample \\
size: 235 \\
Pain, "Numeric rating scale" (Neck pain score) [convergent] \\
Pearson's correlation: \\
0.72 ; total sample size: \\
235
\end{tabular} \& Sufficient

Sufficient \& High
High <br>

\hline | Pain, "Numeric rating scale" |
| :--- |
| (Neck pain scores) | \& | $\mathrm{mJOA}$ |
| :--- |
| Pearson's correlation: -0.07; total sample size: 235 | \& Sufficient \& High <br>


\hline QuickDASH \& | SF-36 |
| :--- |
| Spearman's rank correlation: -0.75 ; total sample size: 94 | \& Sufficient \& Moderate <br>

\hline \& NDI and Pain, "Numeric rating scale" [convergent] \& Sufficient \& Moderate <br>
\hline
\end{tabular}

|  | Spearman's rank correlation range 0.69-0.83; total sample size: 94 |  |  |
| :---: | :---: | :---: | :---: |
| SF-12 |  |  |  |
| MCS | $\begin{aligned} & \text { mJOA } \\ & \quad \text { Pearson's correlation: } \\ & 0.19 \text {; total sample size: } \\ & 235 \end{aligned}$ | Sufficient | High |
|  | Pain, "Numeric rating scale" (Arm pain score) <br> Pearson's correlation: <br> -0.23 ; total sample size: 235 <br> Pain, "Numeric rating scale" (Neck pain score) <br> Pearson's correlation: <br> -0.28; total sample <br> size: 235 | Sufficient | High |
|  | NDI <br> Spearman's rank correlation: -0.17; total sample size: 92 | Sufficient | Moderate |
|  | $\begin{aligned} & \text { SF-12 PCS } \\ & \quad \text { Pearson's correlation: } \\ & \text { 0.01; total sample size: } \\ & 235 \end{aligned}$ | Sufficient | High |
| PCS | $\mathrm{mJOA}$ <br> Pearson's correlation: <br> 0.43 ; total sample size: <br> 235 | Sufficient | High |
|  | Pain, "Numeric rating scale" (Arm pain score) <br> Pearson's correlation: <br> -0.44 ; total sample <br> size: 235 <br> Pain, "Numeric rating <br> scale" (Neck pain score) | Sufficient | High |


|  | Pearson's correlation: -0.41; total sample size: 235 |  |  |
| :---: | :---: | :---: | :---: |
|  | NDI <br> Spearman's rank correlation: -0.49; total sample size: 92 | Sufficient | Moderate |
|  | SF-12 MCS <br> Spearman's rank correlation: -0.29; total sample size: 92 | Sufficient | Low |
| Triangle step test | Grip-and-release test [convergent] <br> Spearman's rank correlation: 0.55 ; total sample size: 270 | Sufficient | High |

*Instruments listed are comparators

## Supplementary Table 12. Responsiveness.

| Instrument | Result summary* | Overall rating | Quality of evidence |
| :---: | :---: | :---: | :---: |
| 30MWT | 30MWT <br> SRM: 0.3; total sample <br> size: 484 | Insufficient | High |
| BBS | mJOA <br> Sensitivity range 77.480.0; total sample size: <br> 31 <br> Specificity range 87.892.9; total sample size: 31 | Sufficient | Low |
| EQ-5D | EQ-5D <br> Mean change score: <br> 0.06 ; total sample size: $108$ | Indeterminate | High |
| European <br> Myelopathy Scale | EMS <br> Normalised change: <br> 0.18 ; total sample size: <br> 99 | Indeterminate | Very low |
| Foot tapping test | Foot tapping test <br> Mean change score: 6; total sample size: 6 | Indeterminate | Very low |
| Grip-and-release test | Grip-and-release test <br> Spearman's rank <br> correlation: 0.69; total <br> sample size: 48 | Sufficient | Very low |
|  | JOA <br> Spearman's rank correlation: 0.32; total sample size: 48 | Insufficient | Low |
| JOA | $\mathrm{mJOA}$ <br> Spearman's rank correlation: 0.75 ; total sample size: 92 | Sufficient | Very low |
|  | JOA | Indeterminate | Very low |

Mean change score
range 4.6; total sample
size: 126
Normalised change:
0.21 ; total sample size:

99
JOA MFLE
Mean change score
range 0.6 ; total sample
size: 126

| JOACMEQ |  |  |  |
| :---: | :---: | :---: | :---: |
| Bladder function | JOACMEQ BF <br> AUC: 0.82; total sample size: 78 | Sufficient | Moderate |
|  | JOACMEQ BF <br> Mean change score: <br> 18.0; total sample size: <br> 87 | Indeterminate | Very low |
|  | JOACMEQ BF <br> Effect size: 0.33; total sample size: 78 | Insufficient | Moderate |
| Cervical <br> spine <br> function | JOACMEQ CF <br> AUC: 0.72; total sample size: 78 | Sufficient | Moderate |
|  | JOACMEQ CF <br> Mean change score: <br> 25.8; total sample size: <br> 87 | Indeterminate | Very low |
|  | JOACMEQ CF <br> Effect size: 0.28 ; total sample size: 78 | Insufficient | Moderate |
| Lower <br> extremity <br> function | JOACMEQ LEF <br> AUC: 0.75; total sample size: 78 | Sufficient | Moderate |
|  | JOACMEQ LEF <br> Mean change score: <br> 28.4; total sample size: | Indeterminate | Very low |


|  | JOACMEQ LEF <br> Effect size: 0.02; total sample size: 78 | Insufficient | Moderate |
| :---: | :---: | :---: | :---: |
| Upper extremity function | JOACMEQ UEF <br> AUC: 0.74; total sample size: 78 | Sufficient | Moderate |
|  | JOACMEQ UEF <br> Mean change score: <br> 10.7; total sample size: <br> 87 | Indeterminate | Very low |
|  | JOACMEQ UEF <br> Effect size: 0.17; total sample size: 78 | Insufficient | Moderate |
| QOL | JOACMEQ QOL <br> AUC: 0.83; total sample size: 78 | Sufficient | Moderate |
|  | JOACMEQ QOL <br> Mean change score: <br> 23.7; total sample size: <br> 87 | Indeterminate | Very low |
|  | JOACMEQ QOL <br> Effect size: 0.46; total sample size: 78 | Insufficient | Moderate |
| MDI | MDI <br> Normalised change: <br> 0.52 ; total sample size: <br> 99 | Indeterminate | Very low |
| mJOA | $\begin{aligned} & \text { mJOA } \\ & \text { Effect size range } 0.87- \\ & 1.0 ; \text { total sample size: } \\ & 352 \end{aligned}$ | Sufficient | High |
|  | mJOA <br> Normalised change: <br> 1.47; total sample size: <br> 42 | Indeterminate | Very low |
| NDI | Anchor-based approach AUC: 0.66; total sample size: 78 | Insufficient | Moderate |


|  | Effect size: 0.44; total sample size: 78 |  |  |
| :---: | :---: | :---: | :---: |
|  | NDI <br> Mean change score: 15.8; total sample size: $118$ | Indeterminate | Very low |
| Nurick scale | Nurick scale <br> Normalised change: <br> 0.42 ; total sample size: <br> 99 <br> Mean change score range -0.76 to -1.3 ; total sample size: 93 | Indeterminate | Very low |
| Ranawat classification of disease severity | Ranawat classification of disease severity <br> Normalised change: <br> 0.34 ; total sample size: 99 | Indeterminate | Very low |
| SF-12 |  |  |  |
| PCS | SF-12 PCS <br> Mean change score: <br> 8.17; total sample size: <br> 118 | Indeterminate | Very low |
| SF-36 | SF-36 <br> Normalised change: <br> 0.32 ; total sample size: $99$ | Indeterminate | Very low |
| PCS | SF-36 PCS <br> Effect size range: 0.84; total sample size: 142 | Sufficient | Low |
|  | SF-36 PCS <br> Sensitivity: 0.85 ; total sample size: 105 | Sufficient | Moderate |
| MCS | SF-36 MCS <br> Effect size range: 0.81; <br> total sample size: 142 | Sufficient | Low |
|  | SF-36 MCS | Sufficient | Moderate |

Sensitivity: 0.67; total
sample size: 105

| WHOQOL-Bref |  |  |  |
| :---: | :---: | :---: | :---: |
| PH | WHOQOL-Bref PH <br> Effect size: 0.68 ; total sample size: 38 | Insufficient | Low |
| PS | WHOQOL-Bref PS <br> Effect size: 0.39; total sample size: 38 | Insufficient | Low |
| SR | WHOQOL-Bref SR <br> Effect size: 0.03; total sample size: 38 | Insufficient | Low |
| EN | WHOQOL-Bref EN <br> Effect size: 0.45 ; total sample size: 38 | Insufficient | Low |

*Instruments listed are comparators

## REFERENCES

1. Auffinger BM, Lall RR, Dahdaleh NS, Wong AP, Lam SK, Koski T, et al. Measuring surgical outcomes in cervical spondylotic myelopathy patients undergoing anterior cervical discectomy and fusion: assessment of minimum clinically important difference. PLoS One. 2013;8(6):e67408.
2. Augusto MT, Diniz JM, Dantas FLR, Oliveira MF, Rotta JM, Botelho RV. Development of the Portuguese Version of the Modified Japanese Orthopaedic Association Score: CrossCultural Adaptation, Reliability, Validity, and Responsiveness. World Neurosurg. 2018;116:e1092-e7.
3. Azimi P, Rezaei O, Montazeri A. An outcome measure of functionality and quality of life in patients with cervical myelopathy. Iran Red Crescent Med J. 2014;16(6):e8102.
4. Badhiwala JH, Witiw CD, Nassiri F, Akbar MA, Jaja B, Wilson JR, et al. Minimum Clinically Important Difference in SF-36 Scores for Use in Degenerative Cervical Myelopathy. Spine (Phila Pa 1976). 2018;43(21):E1260-e6.
5. Bohm PE, Fehlings MG, Kopjar B, Tetreault LA, Vaccaro AR, Anderson KK, et al. Psychometric properties of the $30-\mathrm{m}$ walking test in patients with degenerative cervical myelopathy: results from two prospective multicenter cohort studies. Spine J. 2017;17(2):211-7.
6. Carreon LY, Glassman SD, Campbell MJ, Anderson PA. Neck Disability Index, short form-36 physical component summary, and pain scales for neck and arm pain: the minimum clinically important difference and substantial clinical benefit after cervical spine fusion. Spine J. 2010;10(6):469-74.
7. Chang H, Kong CG, Won HY, Kim JH, Park JB. Inter- and intra-observer variability of a cervical OPLL classification using reconstructed CT images. Clin Orthop Surg. 2010;2(1):8-12.
8. Chiba K, Kato Y, Tsuzuki N, Nagata K, Toyama Y, Iwasaki M, et al. Computer-assisted measurement of the size of ossification in patients with ossification of the posterior longitudinal ligament in the cervical spine. J Orthop Sci. 2005;10(5):451-6.
9. Chien A, Lai DM, Cheng CH, Wang SF, Hsu WL, Wang JL. Responsiveness of the Chinese versions of the Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire and Neck Disability Index in postoperative patients with cervical spondylotic myelopathy. Spine (Phila Pa 1976). 2015;40(17):1315-21.
10. Chiu AY, Pang MY. Assessment of psychometric properties of various balance assessment tools in persons with cervical spondylotic myelopathy. journal of orthopaedic \& sports physical therapy. 2017;47(9):673-82.
11. Fukui M, Chiba K, Kawakami M, Kikuchi S, Konno S, Miyamoto M, et al. Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ): Part 2. Endorsement of the alternative item. J Orthop Sci. 2007;12(3):241-8.
12. Fukui M, Chiba K, Kawakami M, Kikuchi S, Konno S, Miyamoto M, et al. Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire: part 3. Determination of reliability. J Orthop Sci. 2007;12(4):321-6.
13. Goyal DKC, Murphy HA, Hollern DA, Divi SN, Nicholson K, Stawicki C, et al. Is the Neck Disability Index an Appropriate Measure for Changes in Physical Function After Surgery for Cervical Spondylotic Myelopathy? Int J Spine Surg. 2020;14(1):53-8.
14. Gwinn DE, lannotti CA, Benzel EC, Steinmetz MP. Effective lordosis: analysis of sagittal spinal canal alignment in cervical spondylotic myelopathy. J Neurosurg Spine. 2009;11(6):66772.
15. Hosono N, Sakaura H, Mukai Y, Kaito T, Makino T, Yoshikawa H. A simple performance test for quantifying the severity of cervical myelopathy. J Bone Joint Surg Br. 2008;90(9):12103.
16. Hosono N, Takenaka S, Mukai Y, Makino T, Sakaura H, Miwa T, et al. Postoperative 24hour result of 15 -second grip-and-release test correlates with surgical outcome of cervical compression myelopathy. Spine (Phila Pa 1976). 2012;37(15):1283-7.
17. Kang Y, Lee JW, Koh YH, Hur S, Kim SJ, Chai JW, et al. New MRI grading system for the cervical canal stenosis. AJR Am J Roentgenol. 2011;197(1):W134-40.
18. Kato S, Oshima Y, Oka H, Chikuda H, Takeshita Y, Miyoshi K, et al. Comparison of the Japanese Orthopaedic Association (JOA) score and modified JOA (mJOA) score for the assessment of cervical myelopathy: a multicenter observational study. PloS one. 2015;10(4):e0123022.
19. Kato S, Oshima Y, Matsubayashi Y, Taniguchi Y, Tanaka S, Takeshita K. Minimum Clinically Important Difference and Patient Acceptable Symptom State of Japanese Orthopaedic Association Score in Degenerative Cervical Myelopathy Patients. Spine (Phila Pa 1976). 2019;44(10):691-7.
20. Kato S, Oshima Y, Matsubayashi Y, Taniguchi Y, Tanaka S, Takeshita K. Minimum clinically important difference in outcome scores among patients undergoing cervical laminoplasty. Eur Spine J. 2019;28(5):1234-41.
21. King JT, Jr., Roberts MS. Validity and reliability of the Short Form-36 in cervical spondylotic myelopathy. J Neurosurg. 2002;97(2 Suppl):180-5.
22. Ko S, Choi W, Chae S. Comparison of inter- and intra-observer reliability among the three classification systems for cervical spinal canal stenosis. Eur Spine J. 2017;26(9):2290-6.
23. Kopjar B, Tetreault L, Kalsi-Ryan S, Fehlings M. Psychometric properties of the modified Japanese Orthopaedic Association scale in patients with cervical spondylotic myelopathy. Spine (Phila Pa 1976). 2015;40(1):E23-8.
24. Latimer M, Haden N, Seeley HM, Laing RJ. Measurement of outcome in patients with cervical spondylotic myelopathy treated surgically. Br J Neurosurg. 2002;16(6):545-9.
25. Longo UG, Berton A, Denaro L, Salvatore G, Denaro V. Development of the Italian version of the modified Japanese orthopaedic association score (mJOA-IT): cross-cultural adaptation, reliability, validity and responsiveness. Eur Spine J. 2016;25(9):2952-7.
26. Lubelski D, Alvin MD, Nesterenko S, Sundar SJ, Thompson NR, Benzel EC, et al. Correlation of quality of life and functional outcome measures for cervical spondylotic myelopathy. Journal of Neurosurgery: Spine. 2016;24(3):483-9.
27. Mihara H, Kondo S, Murata A, Ishida K, Niimura T, Hachiya M. A new performance test for cervical myelopathy: the triangle step test. Spine (Phila Pa 1976). 2010;35(1):32-5.
28. Nakamoto H, Oshima Y, Takeshita K, Chikuda H, Ono T, Taniguchi Y, et al. Usefulness of QuickDASH in patients with cervical laminoplasty. J Orthop Sci. 2014;19(2):218-22.
29. Nakashima H, Yukawa Y, Ito K, Machino M, Kanbara S, Morita D, et al. Validity of the 10-s step test: prospective study comparing it with the 10-s grip and release test and the 30m walking test. Eur Spine J. 2011;20(8):1318-22.
30. Nicholson KJ, Millhouse PW, Pflug E, Woods B, Schroeder GD, Anderson DG, et al. Cervical Sagittal Range of Motion as a Predictor of Symptom Severity in Cervical Spondylotic Myelopathy. Spine (Phila Pa 1976). 2018;43(13):883-9.
31. Nikaido T, Kikuchi S, Yabuki S, Otani K, Konno S. Surgical treatment assessment using the Japanese orthopedic association cervical myelopathy evaluation questionnaire in patients
with cervical myelopathy: a new outcome measure for cervical myelopathy. Spine (Phila Pa 1976). 2009;34(23):2568-72.
32. Numasawa T, Ono A, Wada K, Yamasaki Y, Yokoyama T, Aburakawa S, et al. Simple foot tapping test as a quantitative objective assessment of cervical myelopathy. Spine (Phila Pa 1976). 2012;37(2):108-13.
33. Olindo S, Signate A, Richech A, Cabre P, Catonne Y, Smadja D, et al. Quantitative assessment of hand disability by the Nine-Hole-Peg test (9-HPT) in cervical spondylotic myelopathy. Journal of Neurology, Neurosurgery \& Psychiatry. 2008;79(8):965-7.
34. Park H-J, Kim SS, Chung E-C, Lee S-Y, Park N-H, Rho M-H, et al. Clinical correlation of a new practical MRI method for assessing cervical spinal canal compression. American Journal of Roentgenology. 2012;199(2):W197-W201.
35. Pratali RR, Smith JS, Motta RL, Martins SM, Motta MM, Rocha RD, et al. A Brazilian Portuguese cross-cultural adaptation of the modified JOA scale for myelopathy. Clinics. 2017;72:103-5.
36. Pratali RR, Smith JS, Rocha RD, Matos TD, Defino HLA, Herrero C. RELIABILITY OF A BRAZILIAN PORTUGUESE TRANSLATED AND CROSS-CULTURALLY ADAPTED VERSION OF THE MJOA SCALE. Acta Ortop Bras. 2018;26(5):335-7.
37. Rhee JM, Shi WJ, Cyriac M, Kim JY, Zhou F, Easley KA, et al. The P-mJOA: A Patientderived, Self-reported Outcome Instrument for Evaluating Cervical Myelopathy: Comparison with the mJOA. Clin Spine Surg. 2018;31(2):E115-e20.
38. Sato T, Horikoshi T, Watanabe A, Uchida M, Ishigame K, Araki T, et al. Evaluation of cervical myelopathy using apparent diffusion coefficient measured by diffusion-weighted imaging. AJNR Am J Neuroradiol. 2012;33(2):388-92.
39. Shim E, Lee JW, Lee E, Kang Y, Kang HS, Kang WY, et al. Cervical spondylotic myelopathy: diagnostic performance of radiologists with varying levels of experience in comparing MR images acquired using field strengths of 1.5 and 3 Tesla. Acta Radiol. 2019;60(10):1314-20.
40. Singh A, Crockard HA. Comparison of seven different scales used to quantify severity of cervical spondylotic myelopathy and post-operative improvement. J Outcome Meas. 2001;5(1):798-818.
41. Singh A, Crockard HA. Quantitative assessment of cervical spondylotic myelopathy by a simple walking test. Lancet. 1999;354(9176):370-3.
42. Singh A, Gnanalingham K, Casey A, Crockard A. Quality of life assessment using the Short Form-12 (SF-12) questionnaire in patients with cervical spondylotic myelopathy: comparison with SF-36. Spine (Phila Pa 1976). 2006;31(6):639-43.
43. Spurgas MP, Abbas SF, Szewczyk BS, Yim B, Ata A, German JW. The effect of length of follow-up on substantial clinical benefit thresholds in patients undergoing surgery for cervical degenerative myelopathy. Journal of Clinical Neuroscience. 2019;62:88-93.
44. Tetreault L, Nouri A, Kopjar B, Côté P, Fehlings MG. The Minimum Clinically Important Difference of the Modified Japanese Orthopaedic Association Scale in Patients with Degenerative Cervical Myelopathy. Spine (Phila Pa 1976). 2015;40(21):1653-9.
45. Thakar S, Rajshekhar V. Evaluation of pain as a preference-based health status measure in patients with cervical spondylotic myelopathy undergoing central corpectomy. Acta Neurochir (Wien). 2012;154(2):335-40.
46. Thakar S, Christopher S, Rajshekhar V. Quality of life assessment after central corpectomy for cervical spondylotic myelopathy: comparative evaluation of the 36-Item Short

Form Health Survey and the World Health Organization Quality of Life-Bref. J Neurosurg Spine. 2009;11(4):402-12.
47. Wada E, Fukui M, Takahashi K, Takeuchi D, Hashizume H, Kanamori M, et al. Japanese orthopaedic association cervical myelopathy evaluation questionnaire (JOACMEQ): Part 5. Determination of responsiveness. Journal of Orthopaedic Science. 2019;24(1):57-61.
48. Witayakom W, Paholpak P, Jirarattanaphochai K, Kosuwon W, Sirichativapee W, Wisanuyotin T , et al. Validation of the reliability of the Thai version of the Japanese Orthopaedic Association Cervical Myelopathy Evaluation Questionnaire (JOACMEQ). Journal of Orthopaedic Science. 2016;21(2):124-7.
49. Yonenobu K, Abumi K, Nagata K, Taketomi E, Ueyama K. Interobserver and intraobserver reliability of the japanese orthopaedic association scoring system for evaluation of cervical compression myelopathy. Spine (Phila Pa 1976). 2001;26(17):1890-4; discussion 5. 50. Yukawa Y, Kato F, Ito K, Horie Y, Nakashima H, Masaaki M, et al. "Ten second step test" as a new quantifiable parameter of cervical myelopathy. Spine (Phila Pa 1976). 2009;34(1):826.
51. Zhang Y, Zhou F, Sun Y. Assessment of health-related quality of life using the SF-36 in Chinese cervical spondylotic myelopathy patients after surgery and its consistency with neurological function assessment: a cohort study. Health Qual Life Outcomes. 2015;13(1):17.
52. Zhou F, Zhang Y, Sun Y, Zhang F, Pan S, Liu Z. Assessment of the minimum clinically important difference in neurological function and quality of life after surgery in cervical spondylotic myelopathy patients: a prospective cohort study. Eur Spine J. 2015;24(12):291823.


[^0]:    *Result ratings for BBS were split by statistic used due to their associated differences in sufficiency.

